CCM
Concord Medical Services
About: Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.
Employees: 727
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.09% less ownership
Funds ownership: 0.1% [Q2] → 0% (-0.09%) [Q3]
50% less funds holding
Funds holding: 4 [Q2] → 2 (-2) [Q3]
69% less capital invested
Capital invested by funds: $77.2K [Q2] → $23.7K (-$53.4K) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for CCM.
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
BEIJING , Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medical Products Administration of the People's Republic of China has granted approval to the application for the Registration Certificate for Medical Device for the proton therapy equipment (the "Registration Certificate") made by the Company's equipment supplier on December 6, 2024. As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022.
Neutral
PRNewsWire
1 month ago
Concord Medical Schedules 2024 Annual Meeting of Shareholders
BEIJING , Nov. 13, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2024 annual general meeting of shareholders (the "Meeting") on December 27, 2024, at 10:00 a.m. (Beijing Time).
Neutral
PRNewsWire
2 months ago
Concord Medical Reports Financial Results for the First Half of 2024
BEIJING , Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024 [1].
Neutral
Business Wire
3 months ago
Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM #drilling--Canagold Resources Ltd. (“Canagold” or the “Company”) (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) announces sample assay results from an additional 2 drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Details of the holes are shown in Table 1. Highlights 10.8 grams p.
Neutral
PRNewsWire
3 months ago
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING , Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
Neutral
Business Wire
3 months ago
Canagold Continues to Intercept Strong Mineralization in Resource Expansion Drilling Program at New Polaris
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (“Canagold” or the “Company”) (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA), announces sample assay results from an additional 26 drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Highlights of the gold mineralization that was intersected are s.
Neutral
PRNewsWire
4 months ago
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
BEIJING , Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock Exchange ("NYSE") dated August 6, 2024 (the "Compliance Notice"), notifying the Company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the "NYSE Minimum Price Requirement"). As previously announced, the Company received a letter from the NYSE dated February 12, 2024, notifying the Company that it was below compliance standards due to the trading price of its American Depositary Shares.
Neutral
Business Wire
5 months ago
Canagold Intercepts Strong Mineralization in First Five Resource Expansion Drill Holes at New Polaris
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) announces sample assay results from the first five drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Highlights of the gold mineralization that was intersected in the initial five drill holes are sh.
Neutral
PRNewsWire
5 months ago
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
BEIJING , July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it plans to change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares (the "ADS Ratio") from the current ADS Ratio of one (1) ADS representing three (3) Class A ordinary shares to a new ADS Ratio of one (1) ADS representing thirty (30) Class A ordinary shares. The Company anticipates that the change in the ADS Ratio will be effective on July 30, 2024 (U.S. Eastern Time).
Neutral
Business Wire
6 months ago
Canagold Resources Ltd. Announces Voting Results From Annual General Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company”) announces that at its annual general meeting of shareholders held on June 12, 2024 (the “Meeting”), all directors listed in the Information Circular dated May 9, 2024 were elected. The detailed results are as follows: Nominee Director Votes For % Votes For Votes Withheld % Votes Withheld Sofia Bianchi 93,941,380 99.46 511,258 0.54 Kadri Dagdelen 94,112,959 99.64 339,6.
Charts implemented using Lightweight Charts™